Skip to main content
. 2017 Aug 14;16:333. doi: 10.1186/s12936-017-1983-9

Fig. 2.

Fig. 2

Distribution of day 3 positivity after treatment with artemisinin-based combination therapy (ACT) and molecular markers (k13, pfarps10, pffd and pfmdr2) in six sentinel sites. Day 3 prevalence and high mutant rate of molecular markers were observed in southern Myanmar sites, Myanmar Artemisinin Resistance Containment (MARC) Tier I areas